{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:34:47Z","timestamp":1780472087238,"version":"3.54.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"sponsor, Roche. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In two 52-week phase 1\u2009b trials, s.c.-TCZ (162\u2009mg\/dose) was administered to sJIA patients every week or every 2\u2009weeks (every 10\u2009days before interim analysis) and to pJIA patients every 2\u2009weeks or every 3\u2009weeks with body weight \u226530\u2009kg or &amp;lt;30\u2009kg, respectively. Primary end points were pharmacokinetics, pharmacodynamics and safety; efficacy was exploratory. Comparisons were made to data from phase 3 trials with i.v. tocilizumab (i.v.-TCZ) in sJIA and pJIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Study participants were 51 sJIA patients and 52 pJIA patients aged 1\u201317\u2009years who received s.c.-TCZ. Steady-state minimum TCZ concentration (Ctrough) &amp;gt;5th percentile of that achieved with i.v.-TCZ was achieved by 49 (96%) sJIA and 52 (100%) pJIA patients. In both populations, pharmacodynamic markers of disease were similar between body weight groups. Improvements in Juvenile Arthritis DAS-71 were comparable between s.c.-TCZ and i.v.-TCZ. By week 52, 53% of sJIA patients and 31% of pJIA patients achieved clinical remission on treatment. Safety was consistent with that of i.v.-TCZ except for injection site reactions, reported by 41.2% and 28.8% of sJIA and pJIA patients, respectively. Infections were reported in 78.4% and 69.2% of patients, respectively. Two sJIA patients died; both deaths were considered to be related to TCZ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>s.c.-TCZ provides exposure and risk\/benefit profiles similar to those of i.v.-TCZ. S.c. administration provides an alternative administration route that is more convenient for patients and caregivers and that has potential for in-home use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT01904292 and NCT01904279<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab047","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:39:56Z","timestamp":1611247196000},"page":"4568-4580","source":"Crossref","is-referenced-by-count":32,"title":["Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"first","affiliation":[{"name":"IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia\u2014PRINTO, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I","family":"Brunner","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Foundation Trust & Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany"},{"name":"Department of Pediatric and Adolescents Medicine, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Cuttica","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Hospital Pedro de Elizalde, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Henrickson","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Anton","sequence":"additional","affiliation":[{"name":"Hospital Sant Joan de D\u00e9u, Universitat de Barcelona, Unidad de Reumatolog\u00eda Pedi\u00e1trica, Esplugues de Llobregat (Barcelona), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Lucica","family":"Boteanu","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, University Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada Calvo","family":"Penades","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Minden","sequence":"additional","affiliation":[{"name":"German Rheumatism Research Centre Berlin, Berlin, Germany"},{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 University Medicine, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrike","family":"Schmeling","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Alberta Children\u2019s Hospital and Cumming School of Medicine\/University of Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hufnagel","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg, Department of Paediatrics and Adolescent Medicine, Division of Paediatric Infectious Diseases and Rheumatology, Medical Faculty, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Weiss","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Paediatric Rheumatology, Hackensack, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Ges\u00f9, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Roth","sequence":"additional","affiliation":[{"name":"University of Ottawa and Division of Paediatric Dermatology & Rheumatology, Children\u2019s Hospital of Eastern Ontario, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadina\u00a0","family":"Rubio-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Facultad de Medicina, Departamento de Pediatria, Hospital Universitario \u2018Dr. J. E. Gonz\u00e1lez\u2019, Monterrey, NL, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy C","family":"Hsu","sequence":"additional","affiliation":[{"name":"Roche Innovation Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunethra","family":"Wimalasundera","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wells","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal\u00a0","family":"Bharucha","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Douglass","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Bao","sequence":"additional","affiliation":[{"name":"Genentech, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navita L","family":"Mallalieu","sequence":"additional","affiliation":[{"name":"Roche Innovation Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lovell","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio De","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Ges\u00f9, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"2021100217423836900_keab047-B1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"2021100217423836900_keab047-B2","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"2021100217423836900_keab047-B3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, Paediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"2021100217423836900_keab047-B4","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021100217423836900_keab047-B5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23236","article-title":"Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis","volume":"70","author":"Oen","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2021100217423836900_keab047-B6","first-page":"125","article-title":"Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition","volume":"8","author":"Grevich","year":"2017","journal-title":"Adolesc Health Med Ther"},{"key":"2021100217423836900_keab047-B7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.12688\/f1000research.11327.1","article-title":"New frontiers in the treatment of systemic juvenile idiopathic arthritis","volume":"6","author":"Canny","year":"2017","journal-title":"F1000Res"},{"key":"2021100217423836900_keab047-B8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis","volume":"34","author":"De Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2021100217423836900_keab047-B9","first-page":"493","article-title":"Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis","volume":"10","author":"De Benedetti","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217423836900_keab047-B10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.1780380209","article-title":"Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes","volume":"38","author":"Mangge","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021100217423836900_keab047-B11","first-page":"1403","article-title":"Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis","volume":"24","author":"De Benedetti","year":"1997","journal-title":"J Rheumatol"},{"key":"2021100217423836900_keab047-B12","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"2021100217423836900_keab047-B13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"2021100217423836900_keab047-B14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"2021100217423836900_keab047-B15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021100217423836900_keab047-B16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"2021100217423836900_keab047-B17","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021100217423836900_keab047-B18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021100217423836900_keab047-B19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/PPA.S34958","article-title":"Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review","volume":"8","author":"Besada","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"2021100217423836900_keab047-B20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/PPA.S5835","article-title":"Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy","volume":"3","author":"Barton","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2021100217423836900_keab047-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/msc.110","article-title":"Treatment choices, preferences and decision-making by patients with rheumatoid arthritis","volume":"6","author":"Chilton","year":"2008","journal-title":"Musculoskeletal Care"},{"key":"2021100217423836900_keab047-B22","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2021100217423836900_keab047-B23","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0091270011422812","article-title":"Clarification on precision criteria to derive sample size when designing paediatric pharmacokinetic studies","volume":"52","author":"Wang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2021100217423836900_keab047-B24","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2021100217423836900_keab047-B25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/adc.2010.188946","article-title":"Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)","volume":"96","author":"Ruperto","year":"2011","journal-title":"Arch Dis Child"},{"key":"2021100217423836900_keab047-B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Paediatric Rheumatology Collaborative Study Group\u2014over four decades of pivotal clinical drug research in paediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"2021100217423836900_keab047-B27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.clinthera.2010.07.021","article-title":"Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing","volume":"32","author":"Stubenrauch","year":"2010","journal-title":"Clin Ther"},{"key":"2021100217423836900_keab047-B28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021100217423836900_keab047-B29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/art.34373","article-title":"Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score","volume":"64","author":"Consolaro","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021100217423836900_keab047-B30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/annrheumdis-2013-204186","article-title":"Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score","volume":"73","author":"Consolaro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021100217423836900_keab047-B31","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/acr.22393","article-title":"Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score","volume":"66","author":"Consolaro","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021100217423836900_keab047-B32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021100217423836900_keab047-B33","first-page":"S1","article-title":"Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology","volume":"19","author":"Ruperto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217423836900_keab047-B34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.38984","article-title":"Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial","volume":"67","author":"De Benedetti","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021100217423836900_keab047-B35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3899\/jrheum.170326","article-title":"Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial","volume":"45","author":"Bharucha","year":"2018","journal-title":"J Rheumatol"},{"key":"2021100217423836900_keab047-B36","year":"2003"},{"key":"2021100217423836900_keab047-B37","year":"1998"},{"key":"2021100217423836900_keab047-B38","volume-title":"ACTEMRA\u00ae (tocilizumab) injection, for intravenous or subcutaneous use","year":"2018"},{"key":"2021100217423836900_keab047-B39","volume-title":"RoActemra 20mg\/ml concentrate for solution for infusion"},{"key":"2021100217423836900_keab047-B40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/17512433.2017.1300058","article-title":"Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis","volume":"10","author":"Zhang","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2021100217423836900_keab047-B41","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"2021100217423836900_keab047-B42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40744-016-0043-1","article-title":"Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study","volume":"3","author":"Kivitz","year":"2016","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab047\/36130267\/keab047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4568\/40500316\/keab047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4568\/40500316\/keab047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T17:47:20Z","timestamp":1633196840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/10\/4568\/6121902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab047","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,1,28]]}}}